World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
34058
World Ranking
18972
National Ranking
9456

Overview

Scott D. Berkowitz is affiliated with the University of Colorado Anschutz Medical Campus in the United States. Their primary field of study is Medicine, with a focus on Cardiology and Cardiovascular Medicine, Surgery, Internal Medicine, Pulmonary and Respiratory Medicine, and Epidemiology.

Their research covers several main topics, including:

  • Peripheral Artery Disease Management
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Venous Thromboembolism Diagnosis and Management
  • Atrial Fibrillation Management and Outcomes
  • Acute Ischemic Stroke Management
  • Vascular Procedures and Complications
  • Cerebrovascular and Carotid Artery Diseases

Recent papers co-authored by Scott D. Berkowitz include:

  • "Rivaroxaban in Peripheral Artery Disease after Revascularization," 2020, New England Journal of Medicine
  • "Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty," 2020, JAMA
  • "Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease," 2020, Circulation
  • "Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization," 2020, Circulation
  • "Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)," 2020, Blood Advances

The frequent co-authors of Scott D. Berkowitz are:

  • Sonia S. Anand
  • Eva Muehlhofer
  • Marc P. Bonaca
  • Manesh R. Patel
  • Lloyd Haskell

The most common publication venues for their work include:

  • Journal of the American College of Cardiology (18 publications)
  • Circulation (16 publications)
  • Stroke (6 publications)
  • Journal of the American Heart Association (5 publications)
  • European Heart Journal (4 publications)

Best Publications

  • Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

    Manesh R. Patel;Kenneth W. Mahaffey;Jyotsna Garg;Guohua Pan

  • Oral rivaroxaban for symptomatic venous thromboembolism

    Rupert Bauersachs;Scott D. Berkowitz;Benjamin Brenner;Harry R. Buller

  • Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

    Barry F. Jacobson;Erich Minar;Jaromir Chlumsky;Peter Verhamme

  • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

    Alexander G. G. Turpie;Michael R. Lassen;Bruce L. Davidson;Kenneth A. Bauer

  • Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

    Robert G. Hart;Mukul Sharma;Hardi Mundl;Scott E. Kasner

  • Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia

    B. E. Lewis;D. E. Wallis;S. D. Berkowitz;W. H. Matthai

  • Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

    Jeffrey I. Weitz;Anthonie W.A. Lensing;Martin H. Prins;Rupert Bauersachs

  • Rivaroxaban in Peripheral Artery Disease after Revascularization

    Marc P Bonaca;Rupert M Bauersachs;Sonia S Anand;E Sebastian Debus

  • Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies

    Martin H Prins;Anthonie Wa Lensing;Rupert Bauersachs;Bonno van Bellen

  • Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.

    Judith A. Dent;Scott D. Berkowitz;Jerry Ware;Carol K. Kasper

  • Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

    Charles W. Francis;Scott D. Berkowitz;Jay R. Lieberman

  • Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

    Jean-Noel Fiessinger;Menno V. Huisman;Bruce L. Davidson;Henri Bounameaux

  • Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.

    Alexander G. G. Turpie;Michael Rud Lassen;Bengt I. Eriksson;Michael Gent

  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial

    Benjamin A. Steinberg;Anne S. Hellkamp;Yuliya Lokhnygina;Manesh R. Patel

  • Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials

    Martin H Prins;Anthonie W A Lensing;Tim A Brighton;Roger M Lyons

  • Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction

    Scott D. Berkowitz;Christopher B. Granger;Karen S. Pieper;Kerry L. Lee

  • Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).

    Shaun G. Goodman;Daniel M. Wojdyla;Jonathan P. Piccini;Harvey D. White

  • Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy

    Scott D. Berkowitz;Robert A. Harrington;Michele M. Rund;James E. Tcheng

  • Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty.

    Richard Friedman;Martin Homering;Gerlind Holberg;Scott D. Berkowitz

  • Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

    M. Levi;K. T. Moore;C. F. Castillejos;D. Kubitza

Frequent Co-Authors

Keith A.A. Fox
Keith A.A. Fox University of Edinburgh
Manesh R. Patel
Manesh R. Patel Duke University
Graeme J. Hankey
Graeme J. Hankey University of Western Australia
Kenneth W. Mahaffey
Kenneth W. Mahaffey Stanford University
Daniel E. Singer
Daniel E. Singer Harvard University
Richard C. Becker
Richard C. Becker University of Cincinnati
Jonathan P. Piccini
Jonathan P. Piccini Duke University
Jonathan L. Halperin
Jonathan L. Halperin Icahn School of Medicine at Mount Sinai
Robert M. Califf
Robert M. Califf Duke University
Günter Breithardt
Günter Breithardt University of Münster

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine offers diverse options, many of which can be accessed through flexible online programs. For those looking to start their journey quickly, fast track LPN programs online are a practical way to gain essential nursing credentials and begin working in healthcare in a short time frame.

If you're interested in advanced nursing roles that focus on mental health, consider the psychiatric NP programs. These programs prepare students to address critical needs in mental healthcare and offer the flexibility of online study.

For those drawn to the organizational or business side of healthcare, numerous affordable online options are available. You can find some of the most affordable healthcare administration degrees online for undergraduate study. Likewise, leadership-minded individuals might explore a master's in healthcare administration online, enabling career advancement in hospitals, clinics, or health organizations.

Whether you’re entering clinical practice or healthcare management, these pathways can provide the knowledge, skills, and flexibility necessary for long-term success in the medical field.

Best Scientists Citing Scott D. Berkowitz

Trending Scientists

Recently Published Articles